File(s) under permanent embargo
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
journal contribution
posted on 2023-06-08, 18:31 authored by F Cardoso, A Costa, L Norton, E Senkus, M Aapro, F André, C H Barrios, J Bergh, L Biganzoli, K L Blackwell, M J Cardoso, T Cufer, N El Saghir, Lesley FallowfieldLesley Fallowfield, D Fenech, P Francis, K Gelmon, S H Giordano, J Gligorov, A Goldhirsch, N Harbeck, N Houssami, C Hudis, B Kaufman, I Krop, S Kyriakides, U N Lin, M Mayer, S D Merjaver, E B Nordstrom, O Pagani, A Partridge, F Penault-Llorca, M J Piccart, H Rugo, G Sledge, C Thomssen, L Van't Veer, D Vorobiof, C Vrieling, N West, B Xu, E WinerAdvanced Breast Cancer (ABC) is a treatable but still generally incurable disease. The goals of care are to optimize both length and quality of life. Due to continuous research, several advances have been made, particularly for the HER-2-positive and for Luminal-like subtypes. Notwithstanding these advances, median overall survival of patients with ABC is still only 2–3 years, although the range is wide [1–5], and survival may be longer for patients treated in specialized institutions [6]. Implementation of current knowledge is highly variable among countries and within each country.
History
Publication status
- Published
File Version
- Published version
Journal
The BreastISSN
0960-9776Publisher
ElsevierExternal DOI
Issue
5Volume
23Page range
489-502Department affiliated with
- Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Publications
Full text available
- No
Peer reviewed?
- Yes
Legacy Posted Date
2014-09-26First Compliant Deposit (FCD) Date
2014-09-26Usage metrics
Categories
No categories selectedLicence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC